Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Escitalopram vs duloxetine in major depressed patients with pain

View through CrossRef
ObjectiveEvaluate the efficacy and tolerability of escitalopram and duloxetine in depressive patients with pain.MethodsSample A (escitalopram): 22 patients (15 female and 7 man, mean age 51.75); Sample B (duloxetine) 25 patients (18 female, 7 man, mean age 53,85). They were diagnosed with major depressive disorder according to ICD 10; assessed with HAMD 17 items in baseline, 14, 28, 42, 56 days; CGIS at baseline, 28 and 56 days; CGII at 28 and 56 days.ResultsEscitalopram 10–20 mg/day; duloxetine 60–120 mg/day. Sample A HAMD 17 items: baseline-21.8; 14 days-19.7; 28 days- 17.2; 42 days-13.5; 56 days-11.8. Sample B HAMD 17 items: baseline-22.3; 14 days-19.9; 28 days- 17.4; 42 days-13.2; 56 days-10.5. Item 13(somatic/general) -diffuse or vague muscle aches or heaviness in the arms or legs mean baseline score for Sample A -1.65; Sample B-1.75; 56 days: Sample A-0.80 and Sample B-0.65. CGIS: mean baseline Sample A: 4.2 and Sample B-4.3; 56 days Sample A-1.9 and Sample B-1.5. CGII 56 days: Sample A 7/22 (31.8%) -much improved and 10/22(45.45%) very much improved; Sample B 11/25 (44%) much improved and 14.25(56%) very much improved. We noted mild nausea 20/47, mild restlessness 12/47, mild dizziness 9/47 at the beginning of the treatment (both samples).Conclusions1)Escitalopram and duloxetine are safe and effective treatment.2)Coexistence of depression with physical pain negatively affects the performance in daily activity and quality of life; in such cases the first treatment option could be duloxetine.3)Escitalopram is also efficient in such cases.
Title: Escitalopram vs duloxetine in major depressed patients with pain
Description:
ObjectiveEvaluate the efficacy and tolerability of escitalopram and duloxetine in depressive patients with pain.
MethodsSample A (escitalopram): 22 patients (15 female and 7 man, mean age 51.
75); Sample B (duloxetine) 25 patients (18 female, 7 man, mean age 53,85).
They were diagnosed with major depressive disorder according to ICD 10; assessed with HAMD 17 items in baseline, 14, 28, 42, 56 days; CGIS at baseline, 28 and 56 days; CGII at 28 and 56 days.
ResultsEscitalopram 10–20 mg/day; duloxetine 60–120 mg/day.
Sample A HAMD 17 items: baseline-21.
8; 14 days-19.
7; 28 days- 17.
2; 42 days-13.
5; 56 days-11.
8.
Sample B HAMD 17 items: baseline-22.
3; 14 days-19.
9; 28 days- 17.
4; 42 days-13.
2; 56 days-10.
5.
Item 13(somatic/general) -diffuse or vague muscle aches or heaviness in the arms or legs mean baseline score for Sample A -1.
65; Sample B-1.
75; 56 days: Sample A-0.
80 and Sample B-0.
65.
CGIS: mean baseline Sample A: 4.
2 and Sample B-4.
3; 56 days Sample A-1.
9 and Sample B-1.
5.
CGII 56 days: Sample A 7/22 (31.
8%) -much improved and 10/22(45.
45%) very much improved; Sample B 11/25 (44%) much improved and 14.
25(56%) very much improved.
We noted mild nausea 20/47, mild restlessness 12/47, mild dizziness 9/47 at the beginning of the treatment (both samples).
Conclusions1)Escitalopram and duloxetine are safe and effective treatment.
2)Coexistence of depression with physical pain negatively affects the performance in daily activity and quality of life; in such cases the first treatment option could be duloxetine.
3)Escitalopram is also efficient in such cases.

Related Results

Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Abstract Thoracic outlet syndrome (TOS) is a complex and often overlooked condition caused by the compression of neurovascular structures as they pass through the thoracic outlet. ...
Dose–Concentration Relationship and Clinical Outcomes of Duloxetine in Generalized Anxiety Disorder
Dose–Concentration Relationship and Clinical Outcomes of Duloxetine in Generalized Anxiety Disorder
Background/Objectives: This study aimed to investigate plasma duloxetine concentrations, factors influencing these concentrations, and the relationship between plasma levels and cl...
COMPARISON OF DULOXETINE MONOTHERAPY VERSUS DULOXETINE AND GABAPENTIN COMBINATION THERAPY FOR NEUROPATHIC PAIN RELIEF
COMPARISON OF DULOXETINE MONOTHERAPY VERSUS DULOXETINE AND GABAPENTIN COMBINATION THERAPY FOR NEUROPATHIC PAIN RELIEF
Background: Neuropathic pain is a complex and often refractory condition that significantly impairs quality of life. Pharmacological management remains the cornerstone of treatment...
Duloxetine for the Treatment of Major Depressive Disorder
Duloxetine for the Treatment of Major Depressive Disorder
Background. Existing therapies for depression frequently fail to provide full remission. This report evaluates the efficacy and safety of duloxetine, a dual reuptake inhibitor of s...
Rise of escitalopram and the fall of citalopram
Rise of escitalopram and the fall of citalopram
Abstract Introduction Citalopram and escitalopram are among the most used medications and are key treatments for many psychiatr...
Acute generalized exanthematous pustulosis induced by duloxetine
Acute generalized exanthematous pustulosis induced by duloxetine
AbstractDuloxetine is a serotonin and norepinephrine reuptake inhibitor. Some rare duloxetine‐induced hypersensitivity skin reactions have been reported. We report a case of acute ...
Impact of Polymorphism of CYP2D6 on Equilibrium Concentration of Duloxetine in Patients Suffering from Major Depressive Disorder
Impact of Polymorphism of CYP2D6 on Equilibrium Concentration of Duloxetine in Patients Suffering from Major Depressive Disorder
Introduction Duloxetine is commonly prescribed to patients with recurrent depressive disorder. Some part of patients in this group do not respond adequately to treatment regimen co...

Back to Top